Entering text into the input field will update the search result below

Rhythm Pharma expects to complete enrollment in late-stage study of setmelanotide in POMC obesity in next quarter

Mar. 12, 2018 4:20 PM ETRhythm Pharmaceuticals, Inc. (RYTM) StockBy: Douglas W. House, SA News Editor
  • In an update to investors, Rhythm Pharmaceuticals (NASDAQ:RYTM) says it expects to initiate a Phase 3 clinical trial this year evaluating setmelanotide in patients with Bardet-Biedl syndrome. Other 2018 setmelanotide-related milestones:
  • Initial data from Phase 2 proof-of-concept study in patients with Alström syndrome, POMC epigenetic disorders and POMC heterozygous deficiency obesity.
  • Enrollment in a Phase 3  study in POMC (proopiomelanocortin) deficiency to be completed next quarter, preliminary data expected in H1 2019 followed by a U.S. marketing application.
  • Enrollment in Phase 3 study in LEPR deficiency obesity to be completed by year-end.
  • The company expects its current level of quick assets to fund operations into H2 2019.

Recommended For You

More Trending News

About RYTM Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
RYTM--
Rhythm Pharmaceuticals, Inc.